SGLT-2 inhibitors were shown to induce a significant reduction in systolic blood pressure (SBP) by 2.46 mm Hg and in diastolic blood pressure (DBP) by 1.46 mm Hg among individuals with T2DM [36]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.